Guideline review highlights updates in colorectal cancer surveillance for inflammatory bowel disease, suggesting improved risk assessment methods.
The 2025 British Society of Gastroenterology guideline on colorectal cancer surveillance in inflammatory bowel disease reflects evolving epidemiology, advances in endoscopic imaging and increasing emphasis on personalised risk assessment. It introduces surveillance guided by multivariate risk modelling with defined risk thresholds, including transition of selected population-risk patients to population-based screening. The guideline also refines biopsy and dysplasia management strategies and highlights the importance of service organisation, audit and surveillance quality. This guideline review summarises the key updates and outlines areas of ongoing uncertainty relevant to clinical practice.
No takes yet. Share an insight, caveat, or question.
Murray et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: